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PERSPECTIVES IN RENAL MEDICINE
Thin basement membrane nephropathy
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Thin basement membrane nephropathy.
Thin basement membrane nephropathy (TBMN) is the most
common cause of persistent glomerular bleeding in children
and adults, and occurs in at least 1% of the population. Most
affected individuals have, in addition to the hematuria, minimal
proteinuria, normal renal function, a uniformly thinned glo-
merular basement membrane (GBM) and a family history of
hematuria. Their clinical course is usually benign.
However, some adults with TBMN have proteinuria 500
mg/day or renal impairment. This is more likely in hospital-
based series of biopsied patients than in the uninvestigated,
but affected, family members. The cause of renal impairment
in TBMN is usually not known, but may be due to secondary
focal segmental glomerulosclerosis (FSGS) or immunoglobulin
A (IgA) glomerulonephritis, to misdiagnosed IgA disease or
X-linked Alport syndrome, or because of coincidental disease.
About 40% families with TBMN have hematuria that segre-
gates with the COL4A3/COL4A4 locus, and many COL4A3
and COL4A4 mutations have now been described. These genes
are also affected in autosomal-recessive Alport syndrome, and
at least some cases of TBMN represent the carrier state for
this condition. Families with TBMN in whom hematuria does
not segregate with the COL4A3/COL4A4 locus can be ex-
plained by de novo mutations, incomplete penetrance of hema-
turia, coincidental hematuria in family members without
COL4A3 or COL4A4 mutations, and by a novel gene locus
for TBMN.
A renal biopsy is warranted in TBMN only if there are
atypical features, or if IgA disease or X-linked Alport syn-
drome cannot be excluded clinically. In IgA disease, there is
usually no family history of hematuria. X-linked Alport syn-
drome is much less common than TBMN and can often be
identified in family members by its typical clinical features
(including retinopathy), a lamellated GBM without the colla-
gen 3(IV), 4(IV), and 5(IV) chains, and by gene linkage
studies or the demonstration of a COL4A5 mutation. Technical
difficulties in the demonstration and interpretation of COL4A3
and COL4A4 mutations mean that mutation detection is not
used routinely in the diagnosis of TBMN.
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Most individuals with thin basement membrane ne-
phropathy (TBMN) have persistent dysmorphic hematu-
ria, minimal proteinuria (500 mg/day) and normal renal
function [1–17]. On ultrastructural examination, their
renal biopsies have a uniformly thinned glomerular base-
ment membrane (GBM) without the long stretches of
lamellation or thickening seen in Alport syndrome. In
addition, there is often another family member with he-
maturia, but not with X-linked Alport syndrome or renal
failure. The prognosis of TBMN is usually excellent.
TBMN is also known as “thin basement membrane
disease,” “benign familial hematuria,” “benign persistent
hematuria,” and “benign essential hematuria.” We have
used the term “TBMN” because it reflects the underlying
ultrastructural abnormality, and because TBMN is not
necessarily a “disease” nor “benign” nor “familial.”
“Benign persistent hematuria” was first reported nearly
80 years ago [1, 18]. This was described as the painless,
microscopic, and often incidental hematuria that occurred
in young adults, without the hypertension or edema seen
in chronic nephritis, and with a good prognosis. It was
another 50 years before the distinctively thinned GBM
was noted [7].
EPIDEMIOLOGY OF TBMN
TBMN has been reported in Caucasians, Chinese, In-
dians, and Africans [19, 28]. The median age at presenta-
tion is 7 years in children [1–6], and 37 years in adults
[7–17], and hematuria from TBMN has been reported
in infants as young as 1 year, and in an 86-year-old [7].
The majority of studies (71%) suggest that TBMN is
more common in females than males (median male:
female ratio  1.6) [1–5, 9–11, 13–16].
The prevalence of TBMN cannot be accurately esti-
mated from population-based studies because many indi-
viduals are unaware they are affected. For example, we
have found that even in families in whom TBMN had
been diagnosed, only half the affected family members
knew they had hematuria [19]. The prevalence of TBMN
may, however, be inferred from the frequency of persis-
tent dysmorphic hematuria in the community. Hematu-
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Table 1. Clinical features in children and adults with biopsy-proven thin-basement membrane nephropathy (TBMN)
Children with TBMN Adults with TBMN
Median (total of 6 studies) (total of 11 studies)
% Patients with loin pain (range) Not commented on in any 14% (7–31%) (3 studies)
of the studies
% Patients with macroscopic hematuria (range) 34% (5–65%) (5 studies) 7% (0–25%) (11 studies)
% Patients with any proteinuria (range) 6% (0–65%) (6 studies) 50% (0–71%) (10 studies)
% Patients with proteinuria 500 mg/day (range) 0% (0–0%) (4 studies) 16% (0–57%) (6 studies)
% Patients with hypertension (140/90 mm Hg) (range) 0% (0–0%) (6 studies) 17% (0–37%) (8 studies)
% Patients with impaired renal function (creatinine 0.11 mmol/L) 0% (0–0%) (4 studies) 0% (0–29%) (7 studies)
In all series, TBMN was confirmed by biopsy in the patient or a family member, and patients were not further identified by a single clinical entity such as ‘isolated
hematuria,’ or known to have a hearing loss or family history of Alport syndrome. Some series of adults included occasional children. The number of studies in
which individual clinical features were noted are provided in parentheses (1–17).
ria on a single occasion is very common, but hematuria
that persists occurs in only 1% to 2% of children [20, 21]
and about 2.5% of adults [22]. Persistent hematuria in
children is usually “dysmorphic” or “glomerular” on phase-
contrast urinary microscopy [23], and although a glomer-
ular origin has not been confirmed in the majority of
adults, most have no urologic cause demonstrated [22, 24].
Thus, persistent hematuria in both children and adults
appears to originate from the glomerulus more often
than from elsewhere in the urinary tract. Furthermore,
many series of children [25–27] and adults [13, 28–30]
with persistent hematuria have demonstrated that
TBMN is the most common histologic diagnosis despite
nephrologists’ reluctance to biopsy patients with normal
renal function.
The frequency of TBMN has also been measured di-
rectly. A thinned GBM was found in 5.2% of a series
of 76 renal transplant biopsies where the definition of
thinning did not overlap with the normal range [31].
Thus, both direct and indirect approaches suggest that
TBMN occurs in more than 1% of the population, which
makes it one of the most common conditions affecting
the kidney after infections, hypertension, and stones.
CLINICAL FEATURES
TBMN is characterized clinically by persistent hema-
turia, minimal proteinuria, normal renal function, another
family member with hematuria, and a benign course. We
reviewed the clinical features in six pediatric and 11 adult
studies (Table 1) [1–17] where TBMN was confirmed by
biopsy in the patient or a family member, and where
patients were not identified by a single clinical entity
such as “isolated hematuria,” and were not known to
have a hearing loss or family history of Alport syndrome.
Children in the pediatric studies had the clinical fea-
tures typical of TBMN, and none had proteinuria 500
mg/day, hypertension, or renal impairment. Proteinuria
of any degree was uncommon, occurring in a median of
6% children (range, 0% to 65%).
In contrast, a median of 50% adults with TBMN had
some degree of proteinuria (range, 0% to 71%), while
16% had proteinuria 500 mg/day (range, 0% to 57%),
and 17% had hypertension (range, 0% to 37%). Most
adults had normal renal function, but 29% in one report
had renal impairment.
What could explain the atypical features in these
adults with TBMN? We compared the clinical features
in 71 of our adults with biopsy-proven TBMN and 45 of
their family members who had not been investigated
previously but who we showed had hematuria and hence
considered affected (Table 2). We found that adults with
TBMN who had undergone renal biopsy were more
likely to have proteinuria 500 mg/day than their un-
biopsied but affected family members (P  0.02); and
while 7% biopsied patients had some degree of renal
impairment, none of their uninvestigated affected rela-
tives did. These observations suggest that adults with
suspected TBMN who undergo renal biopsy have more
severe clinical features than other affected individuals.
Hematuria is characteristic of TBMN. It is usually
“asymptomatic” and may be demonstrated incidentally
during a clinic visit for another complaint, or as part
of a medical examination for insurance or employment
purposes [28]. The hematuria is also described as “iso-
lated” because proteinuria is usually absent or minimal.
The urinary red blood cells are dysmorphic, with an
irregular size and shape, and variable hemoglobin con-
tent typical of glomerular bleeding [32]. These red cells
have escaped through transient 2.25 m wide gaps in
the glomerular endothelium and basement membranes
into the urinary space [33]. Urinary red blood cell counts
on phase-contrast microscopy are often about 150,000/mL
urine, which correspond to 100 to 150 red blood cells
passing through the membranes of each glomerulus
daily. Red blood cell casts are reported less often than
with other glomerular lesions that result in similar levels
of hematuria [28, 29], and unusual hyaline “string casts”
with red blood cell columns have been described [29].
Hematuria does not occur in all patients with TBMN
and, in one report, 8% of patients with biopsy-proven
disease had no glomerular bleeding [11].
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Table 2. Proteinuria and renal impairment in patients with biopsy-proven thin-basement membrane nephropathy (TBMN)
and affected family members
Hospital-based biopsied Affected family members of
patients (N  71) biopsied patients (N  45) P value
Gender 11M, 60F 13M, 32F NS
Age years (median, range) 34 (10–68) 36 (4–71) NS
Proteinuria 500 mg/day 15 (21%) 2 (4%) 0.02
Impaired renal function (serum creatinine 0.11 mmol/L) 5 (7%) 0 (0%) NS
Affected family members were from 18 families of hospital-based biopsied patients and were identified as affected because they had hematuria [30].
In the pediatric and adult studies reviewed here, mac-
roscopic hematuria occurred in 34% children (median,
range, 5% to 65%, in five studies) and 7% adults (me-
dian, range, 0% to 25%, in 11 studies) usually after ex-
ercise or with infections (Table 1). Loin pain was re-
corded in 14% adults (median, range, 7% to 31%, in
three studies), but was not noted in any of the pediatric
reports. The hypothesis that TBMN causes some cases
of “loin pain-hematuria syndrome” [34] has not been
examined further.
Six percent of children (median, range, 0% to 65%,
in six studies) and 50% of adults (median, range, 0% to
71%, in 10 studies) with TBMN had proteinuria but typi-
cally 500 mg/day (Table 1). Nephrotic range protein-
uria and urinary fat are rare. Marked proteinuria is some-
times due to secondary glomerulosclerosis [17, 35] or to
other superimposed glomerular lesions [36]. The amount
of proteinuria does not correlate with the degree of GBM
thinning [13], and it has been unclear how gaps in the
GBM allow red blood cells, but not protein, to escape.
Some of the leaked protein may, however, be resorbed
by the renal tubules.
Hypertension did not occur in any of pediatric studies
but was present in 17% of adults with TBMN (median,
range, 0% to 37%, in eight studies) (Table 1). This may
be coincidental.
Most individuals with TBMN have normal renal func-
tion, but renal impairment is sometimes present in adults
(median, 0%, range, 0% to 29%, in seven studies). The
cause of renal impairment is often unknown, and protein-
uria and hypertension are the only known risk factors.
Renal impairment also occurs because of a secondary
glomerulonephritis [17, 35–40], misdiagnosed X-linked
Alport syndrome or immunoglobulin A (IgA) disease,
or coincidental disease [41]. IgA glomerulonephritis oc-
curs in 2% to 39% of different series of patients with
TBMN [36–39], probably more often than by chance
alone. Patients with both TBMN and IgA disease have
the persistent hematuria seen with TBMN, but are not
more likely to have proteinuria, hypertension or renal
impairment than patients with uncomplicated IgA dis-
ease [39]. Focal segmental glomerulosclerosis (FSGS)
occurs in at least 5% of patients with TBMN [17]. Sys-
temic lupus erythematosus (SLE), membranous nephri-
tis, diabetes, and mesangiocapillary glomerulonephritis
have all been described in patients with TBMN [36], but
TBMN is so common that these associations may be
by chance. In contrast, the thinned GBM sometimes
described in minimal change glomerulonephritis is prob-
ably artifactual [42].
TBMN appears to have no extrarenal manifestations
and, in particular, the high-tone sensorineural hearing
loss, anterior lenticonus, and dot-and-fleck retinopathy
seen in Alport syndrome, another inherited disease af-
fecting the GBM, do not occur [43]. Hypercalciuria,
hyperuricosuria, and nephrolithiasis have been described
in TBMN [44] but not confirmed [5, 6].
RENAL BIOPSY FEATURES
The light microsopic appearance of the renal biopsy
in TBMN is nearly normal with only mild mesangial
cell proliferation and slight matrix expansion [29, 45].
Premature glomerular sclerosis [17] and tubulointersti-
tial fibrosis may occur. Small mesangial deposits of IgM,
C3, and C1q are seen sometimes but are nonspecific [29].
The GBM width is thinner in children than in adults,
and in adult females compared with males. The diagnosis
of TBMN is made when the GBM width on electron
micrographs is less than the normal range established
for individual laboratories [46, 47] (Fig. 1). The criteria
for TBMN in children vary from 200 to 250 nm de-
pending on age [48], and in adults from 200 nm [36],
250 nm [12] (World Health Organization criteria)
to 264 nm [29] partly because of technical differences
in tissue processing. In TBMN, the GBM is thinned in
the majority of capillary loops, and at least 50% of the
GBM is thinned in individual capillaries. There are only
isolated regions of lamellation or thickening, and there
is no progressive thickening or splitting over time.
TBMN has to be distinguished from the GBM thinning
seen in normal children [49], and in IgA [50], minimal
change, mesangiocapillary, and some forms of lupus glo-
merulonephritis [45]. While the GBM thinning in chil-
dren is diffuse, the thinning in most of these glomerular
diseases is focal.
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Fig. 1. Ultrastructural appearance of glomerular basement membrane
(GBM). (A ) Individual with thin basement membrane nephropathy
(TBMN) showing uniform thinning (6300). (B ) Carrier of autosomal-
recessive Alport syndrome showing uniform thinning (550). (C ) A
9-year-old boy with X-linked Alport syndrome showing thinning
(arrow) and lamellation (6000). (D ) Female carrier with X-linked
Alport syndrome showing thinning (arrow) and lamellation (small
arrow) (9000). (E) Normal individual (6300).
GENETICS OF TBMN
Two thirds of individuals with TBMN have at least
one other hematuric family member when five relatives
are tested [19], and the inheritance of hematuria in such
families is autosomal dominant [28] (Fig. 2). The con-
verse of this observation is, however, that one third of
individuals with TBMN have no family members with
Fig. 2. Pedigree showing the inheritance of hematuria in two intermar-
ried families with thin basement membrane nephropathy (TBMN).
Half-shaded symbols indicate hematuria and heterozygosity for the
causative mutation inherited from a parent; fully shaded symbols in-
dicate the compound heterozygous state with mutations from both
hematuric parents. The hematuria occurs in each generation, and males
and females are affected equally often, suggesting autosomal-dominant
inheritance. This is confirmed by the demonstration of a father and son
who both have hematuria (but not renal failure). In generation III, the
offspring of two parents with hematuria are compound heterozygous
(with diseased genes from their father and mother) or heterozygous
for mutations (from either their father or mother) or have normal genes,
in a ratio of 1:2:1. Although TBMN may represent the carrier state for
autosomal-recessive Alport syndrome, it is not clear that one in four
of all offspring of two parents with TBMN necessarily develops Alport
syndrome with renal failure, deafness, lenticonus, and retinopathy.
hematuria. This apparent lack of affected family mem-
bers can still be explained by a genetic disorder if muta-
tions occur de novo or hematuria is incompletely pene-
trant.
The genetic nature of TBMN was unclear for many
years, and immunohistochemical examination of the
thinned GBM showed only that it comprised all 1(IV)
to 5(IV) type IV collagen chains (including the Good-
pasture epitope) [51, 52]. It was the demonstration of
uniform GBM thinning in carriers of autosomal-reces-
sive Alport syndrome [53] that first suggested TBMN
represented the carrier state for autosomal-recessive dis-
ease or at least affected the same genes [19, 54–56] (Fig.
1) (A thinned GBM also occurs in young males and fe-
male carriers with X-linked Alport syndrome but this
condition must be distinguished from TBMN because of
its very different prognosis). We and others have now
shown that at least 40% of individuals with biopsy-
proven TBMN are from families where hematuria segre-
gates with COL4A3/COL4A4 locus for autosomal-reces-
sive Alport syndrome, despite there being no family
members with this condition [19, 57]. Our laboratory
subsequently demonstrated the R1377X and S969X
COL4A4 mutations in both TBMN and autosomal-
recessive Alport syndrome [58, 59], thereby confirming
that TBMN may represent the carrier state for autoso-
mal-recessive Alport syndrome.
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The observation that TBMN sometimes represents the
carrier state for autosomal-recessive Alport syndrome
means that the offspring of two parents with TBMN
may be at risk of developing autosomal-recessive Alport
syndrome with kidney failure, hearing loss, lenticonus,
and retinopathy. On average, one in four offspring will
be compound heterozygotes for the causative mutations
and are at risk. It is not clear, however, that compound
heterozygotes necessarily develop Alport syndrome or
whether they simply have hematuria.
The autosomal-dominant nature of inheritance of
TBMN is still consistent with inheritance of the carrier
state for autosomal-recessive Alport syndrome (Fig. 2).
It is also consistent with the apparent increased preva-
lence of TBMN in females, despite males and females
inheriting the causative mutations equally often. The
increased prevalence in females can be explained by
mutations resulting in further attenuation of their nor-
mally thinner GBM and thus higher urinary red blood
cell counts and an increased likelihood of detection.
Many COL4A3 and COL4A4 mutations have now
been reported in TBMN [57, 60–62]. As in other diseases
affecting the COL4 genes, mutations are usually differ-
ent in each family and there is no “hotspot.” In addition
many mutations result in the substitution of glycine with
larger, more highly charged residues that disrupt the
collagen triple helix. Few studies have correlated muta-
tions and clinical features in TBMN, but preliminary
evidence suggests that mutations that result in glycine
substitutions or stop codons do not necessarily affect the
penetrance of hematuria or the development of protein-
uria [62]. The only mutation described to date that has
been associated with incompletely penetrant hematuria
is P1132L in COL4A4 [62].
The mutation detection rate in TBMN is low even
when both COL4A3 and COL4A4 genes are examined.
This is partly because of the relatively insensitive screen-
ing methods used and because the commonly used
primer sets do not detect all splice-site mutations. Muta-
tion detection is further complicated by frequent COL4A3
and COL4A4 polymorphisms and the difficulty in distin-
guishing mutations from rare sequence variants in non-
hematuric controls who have not had TBMN excluded
by biopsy. Mutation detection is not used currently in
the routine diagnosis of TBMN.
Heterozygous COL4A3 and COL4A4 mutations also
cause autosomal-dominant Alport syndrome [63, 64],
which results in renal failure, hearing loss, and a lamel-
lated GBM. Few mutations have been described in this
form of Alport syndrome and it is not obvious how they
differ from the heterozygous COL4A3 and COL4A4
mutations that cause the milder TBMN phenotype.
We and others have shown many families with TBMN
have hematuria that does not segregate with the COL4A3/
COL4A4 locus [65, 66], but these families may still have
mutations in the COL4A3 and COL4A4 genes if de novo
mutations occur, hematuria is incompletely penetrant in
some family members, or family members without the
mutations have coincidental hematuria. These explana-
tions may account for the majority of families with
TBMN where hematuria does not segregate with the
COL4A3/COL4A4 locus because: the de novo muta-
tion rate in COL4A3 and COL4A4 is 30% if mutations
in both genes occur at the same rate (15%) as in the
COL4A5 gene in X-linked Alport syndrome [67]; the in-
complete penetrance rate of hematuria at the COL4A3/
COL4A4 locus is about 20% in heterozygous carriers
of autosomal-recessive Alport syndrome [59]; and 14%
family members without the TBMN disease haplotypes
have coincidental hematuria [19].
On the other hand, TBMN that does not segregate
with the COL4A3/COL4A4 locus could be explained by
mutations in a novel gene. The MYH9 gene on 22q
represented a further possible locus for TBMN, because
MYH9 mutations result in an autosomal-dominant Al-
port-like syndrome [68], because the autosomal-reces-
sive and dominant forms of a disease often affect the
same gene, and because TBMN is sometimes the carrier
state for autosomal-recessive Alport syndrome. How-
ever, our laboratory has been unable to demonstrate
linkage to this locus in any of eight families with TBMN
that did not segregate with COL4A3/COL4A4 previously.
It remains unclear whether there is a further genetic locus
for TBMN and, if there is, what this might be.
RISKS OF TBMN
The commonly used alternative name “benign familial
hematuria,” as well as numerous reports, attest to the
generally excellent prognosis of TBMN. No specific ther-
apy is available but hypertension, proteinuria, and renal
impairment may need treatment.
The most common hazards of TBMN are the misun-
derstanding and anxiety associated with this diagnosis,
and the risks and wastefulness of unnecessary investiga-
tions. Nevertheless, some patients with TBMN develop
renal impairment and the reasons for this, apart from
hypertension and proteinuria being predisposing factors,
are unknown.
There are also genetic implications of making the diag-
nosis of TBMN. On average, half the offspring of any
affected individual will have the causative mutation and
about half will have hematuria, depending on its level
of penetrance. It is not, however, known how often the
offspring of two parents with TBMN will develop autoso-
mal-recessive Alport syndrome.
Can individuals with TBMN be kidney donors? Many
nephrologists currently use kidneys from donors with
TBMN, and there are many anecdotal instances where
there have been no apparent adverse outcomes. The real
risks of donation and the outcome for the recipients are,
however, unknown.
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Table 3. Clinical features in hospital-based patients with biopsy-proven thin-basement membrane nephropathy (TBMN)
or immunoglobin A (IgA) glomerulonephritis
IgA glomerulonephritis
TBMN (N  71) (N  32) P value
Gender 11M, 60F 22M, 10F 0.001
Age years (median, range) 34 (10–68) 31 (5–61) NS
Reported macroscopic hematuria 13 (18%) 10 (31%) NS
Any proteinuria 33 (46%) 21 (66%) NS
Proteinuria 500 mg/day 15 (21%) 21 (66%) 0.001
Hypertension 14 (20%) 10 (31%) NS
Renal impairment 5 (7%) 7 (22%) 0.05
This study [30] suggested a family history of hematuria was infrequent in both TBMN and IgA disease. However, other reports have found two thirds of individuals
with TBMN have another family member with hematuria, while only 5% to 10% patients with IgA disease have hematuria.
DIFFERENTIAL DIAGNOSIS
The two most important conditions that TBMN must
be distinguished from are IgA glomerulonephritis and
X-linked Alport syndrome. IgA disease is common and
may resemble TBMN clinically. However, it occurs more
often in males and typically has fluctuating urinary red
blood cell counts (hematuria is macroscopic during infec-
tions and microscopic between these episodes), and often
proteinuria 500 mg/day, and progressive renal impair-
ment (Table 3). Fewer than 10% individuals with IgA
disease have another family member with hematuria
[28, 30] and this may be coincidental rather than indicat-
ing inherited disease.
TBMN must also be distinguished from other common
glomerular diseases that cause hematuria. These are post-
streptococcal, mesangiocapillary, proliferative lupus, and
crescentic glomerulonephritis. In all these conditions, the
symptoms are usually of recent and sudden onset, and
macroscopic hematuria, proteinuria, hypertension, and
renal impairment as well as systemic features may be
present. There is no family history of hematuria.
It is not usually difficult to differentiate TBMN from
other less common inherited diseases that result in glo-
merular bleeding. These include familial FSGS (in which
proteinuria predominates but low levels of hematuria
may occur), sickle cell nephropathy (which occurs in
heterozygotes as well as homozygotes), and mesangio-
capillary glomerulonephritis type II (in which there is
usually distinctive lipodystrophy and retinopathy).
DISTINCTION FROM X-LINKED
ALPORT SYNDROME
It is important to distinguish TBMN from X-linked
Alport syndrome, especially in young males and in fe-
males because of the very different prognoses for these
conditions.
X-linked Alport syndrome is uncommon, occurring in
1 in 50,000 live births [69], and young males often have
proteinuria500 mg/day and renal impairment, in addi-
tion to the hematuria, while children with TBMN do
not [1–6] (Table 4). In addition, the demonstration of a
bilateral hightone sensorineural hearing loss is specific
for Alport syndrome and is often present in childhood.
While anterior lenticonus and the dot-and-fleck retinop-
athy are also diagnostic of Alport syndrome [70], they
are often not evident until the third decade (Fig. 3).
About 95% female carriers of X-linked Alport syn-
drome have hematuria [71, 72], but they cannot be distin-
guished from individuals with TBMN on the basis of
proteinuria500 mg/day or renal impairment (Table 4).
While the typical hearing loss, lenticonus, and retinopa-
thy are again diagnostic for Alport syndrome, they are
found in fewer than 10% female carriers in adulthood
[71, 72].
In both young males and female carriers with hematu-
ria, a family history of renal failure often helps distin-
guish between TBMN and X-linked Alport syndrome,
and patients should be encouraged to actively seek out
the medical details of distant relatives. Where the nature
of the renal failure in the distant family member is not
known, it is often useful to examine that person for
the characteristic hearing loss, lenticonus, or retinopathy
(retinal photography is particularly helpful). It must be
emphasized that the bilateral high tone sensorineural
hearing loss is highly suggestive of Alport syndrome, and
the lenticonus and distinctive retinopathy do not occur
in any other condition. The absence of these features
does not, of course, exclude Alport syndrome since they
are not present in 25% patients.
It remains difficult to diagnose X-linked Alport syn-
drome clinically in families where there are few males,
no males are affected, the males are too young to demon-
strate the clinical phenotype, or the phenotype is atypi-
cal, for example, renal failure develops in later life or
hearing is normal. X-linked Alport syndrome is also dif-
ficult to diagnose in families where the mutation has
occurred in the present generation and there are no
other affected family members. Although most X-linked
Alport carriers have hematuria, and it should be possible
to confirm the X-linked nature of the inheritance of
hematuria and renal failure within their families, this is
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Table 4. Clinical features in patients with thin-basement membrane nephropathy (TBMN), and young males and female carriers
with X-linked Alport syndrome
Young males with Female carriers with
X-linked Alport X-linked Alport
TBMN (N  71) syndrome (N  8) syndrome (N  42)
Prevalence Common Uncommon Uncommon
Gender 11M, 60F 8 M 42 F
Age years (median plus range) 34 (10–68) 11 (5–26) 35 (6–85)
Proteinuria 500 mg/day 15 (21%) 3 (38%) (P NS)a 5 (11%) (NS)
Renal impairment 5 (7%) 5 (63%) (0.001) 2 (5%) (NS)
Hearing loss clinically detectable 2 (3%) 4 (50%) (0.001) 2 (5%) (NS)
Known family history of renal failure 3/71 (4%) 6/8 (75%) (0.0001) 35/42 (83%) (0.0001)
The diagnosis of Alport syndrome was demonstrated in all cases by renal biopsy, and X-linked inheritance was confirmed by linkage to the COL4A5 locus. The
eight males with X-linked Alport syndrome were from eight families and the 42 female carriers were from 18 families. Clinical features were compared with the chi-
square test with Yates’ correction for small numbers.
aChildren with TBMN do not have proteinuria 500 mg/day (1–6), and if patients with TBMN were age-matched with the young males with X-linked Alport
syndrome, proteinuria disinguishes between the two groups (P  0.001)
Fig. 3. Retinal photograph showing perimac-
ular white dot-and-fleck retinopathy that is
pathognomonic for Alport syndrome. This is
present in about 70% males with X-linked
Alport syndrome by the age of 20 years and
about 10% female carriers. It is also found in
autosomal-recessive Alport syndrome but not
in carriers or individuals with thin basement
membrane nephropathy (TBMN). The reti-
nopathy is not associated with any visual loss,
and although often evident on ophthalmos-
copy, it is most easily demonstrated with reti-
nal photographs.
often not practicable. It is, however, sometimes possible
to exclude X-linked Alport syndrome from examination
of the pedigree. For example, the presence of adult males
with hematuria but without renal failure or deafness
usually (but not always) excludes X-linked Alport syn-
drome [72]; and the demonstration of a father and son
with hematuria but with normal renal function indicates
autosomal-dominant inheritance and is not compatible
with X-linked disease.
A renal biopsy should be performed to exclude
X-linked Alport syndrome if this is not possible by other
means (Fig. 1) (Table 5). In boys and female carriers
with X-linked disease, the GBM is thinned but there
are also regions of splitting and thickening that worsen
progressively with time and that distinguish the GBM
from that seen in TBMN [73, 74]. In affected adult males
with X-linked Alport syndrome, the GBM is lamellated
and thickened with subepithelial frilling. In 80% of af-
fected males, the GBM, distal tubular basement mem-
brane, and Bowman’s capsule lack the 3(IV), 4(IV)
and 5(IV) chains of type IV collagen, but in female
carriers these molecules are normally or segmentally
present because of lyonization [75, 76]. Immunohisto-
chemical studies may be technically difficult and normal
type IV collagen chain composition does not exclude
Alport syndrome in males or female carriers. Examina-
tion of the type IV collagen composition of epidermal
basement membrane from skin biopsies sometimes help
distinguish between X-linked Alport syndrome (where
the 5(IV) chain is absent in many patients) and TBMN
[77, 78].
Genetic studies are used infrequently in the routine
diagnosis of X-linked Alport syndrome. They can, how-
ever, confirm that hematuria within a family segregates
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Table 5. Ultrastructural, immunohistochemical, and genetic characteristics in patients with thin-basement membrane nephropathy (TBMN),
and young male and female carriers with X-linked Alport syndrome
TBMN Young males with XLAS Female carriers with XLAS
GBM Thinned Thinned with regions of lamellation; Thinned with regions of lamellation;
becomes thickened and more lamellated may thicken and become more
with time lamellated with time
Type IV collagen chains in GBM 3(IV)–5(IV) 3(IV)–5(IV) chains absent from GBM, Normal 3(IV)–5(IV) chain
chains all present distal TBM and Bowman’s capsule in distribution or patchy
80% cases loss
Type IV collagen chains in 5(IV) chain present 5(IV) chain missing Normal 5(IV) chain distribution or
epidermal basement membrane patchy loss
Genes affected COL4A3/COL4A4 COL4A5 COL4A5
and possibly other
loci
Abbreviations are: GBM, glomerular basement membrane; TBM, tubular basement membrane. The genes affected may be implicated by linkage studies or
mutation detection.
with the COL4A5 locus and they can demonstrate the
causative COL4A5 mutations [79]. Linkage studies are
easier and more readily available than mutation detec-
tion but they require the cooperation and characteriza-
tion of many family members. It is usually easier to
exclude linkage than to confirm it, and it may be rela-
tively easy to show that hematuria is not linked to the
COL4A5 gene. Mutation detection is laborious and rela-
tively insensitive, and there is usually no advantage to
knowing the mutations in individual families. There are,
however, several large research centers in Europe that
sequence the COL4A5 gene and can detect more than
80% mutations.
MANAGEMENT OF TBMN
There are no evidence-based guidelines for the man-
agement of patients with TBMN. After this diagnosis has
been made clinically or on renal biopsy, many physicians
begin by monitoring adult patients for the development
of hypertension, proteinuria, or renal impairment every 1
to 2 years. Family doctors may subsequently be involved.
Patients at risk of renal impairment cannot be identified
at presentation apart from those who have proteinuria
or hypertension. Patients with proteinuria500 mg/day,
hypertension, or renal impairment should be treated,
and reviewed regularly. In addition, family members of
patients with TBMN should be offered the opportunity
to be tested for hematuria.
CONCLUSION
TBMN is one of the most common conditions affecting
the kidney, but we are only now coming to acknowledge
its prevalence and to understand its genetic basis. We
still do not know why renal function occasionally deterio-
rates, the relationship between a thinned GBM and sec-
ondary glomerular disease, whether mutations in the
COL4A3 and COL4A4 genes account for all cases of
TBMN, and the consequences, if any, of kidney donation
for both the donor and recipient.
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